Compare BMHL & MXCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | MXCT |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.9M | 136.2M |
| IPO Year | 2024 | 2021 |
| Metric | BMHL | MXCT |
|---|---|---|
| Price | $5.53 | $1.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 2.2K | ★ 403.0K |
| Earning Date | 06-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,026,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.50 |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.72 | $0.64 |
| 52 Week High | $6.35 | $1.86 |
| Indicator | BMHL | MXCT |
|---|---|---|
| Relative Strength Index (RSI) | 44.28 | 49.52 |
| Support Level | $5.45 | $1.19 |
| Resistance Level | $6.17 | $1.30 |
| Average True Range (ATR) | 0.34 | 0.05 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 53.00 | 54.29 |
Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.